{
    "organizations": [],
    "uuid": "b1280bd1a087b3d4f0662a619b0e870cc709f2dc",
    "author": "",
    "url": "https://www.reuters.com/article/brief-enanta-pharmaceuticals-says-phase/brief-enanta-pharmaceuticals-says-phase-1-clinical-study-of-edp-938-for-respiratory-syncytial-virus-initiated-idUSASB0BZVS",
    "ord_in_thread": 0,
    "title": "BRIEF-Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 33 PM / in 9 minutes BRIEF-Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated Reuters Staff 1 Min Read \nJan 5 (Reuters) - Enanta Pharmaceuticals Inc: \n* ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE \n* ENANTA PHARMACEUTICALS INC - PHASE 1 CLINICAL STUDY OF EDP-938 FOR RESPIRATORY SYNCYTIAL VIRUS INITIATED \n* ENANTA PHARMACEUTICALS INC - PHASE 2 CLINICAL STUDY “INTREPID” OF EDP-305 IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS INITIATED \n* ENANTA PHARMACEUTICALS INC - STRONG CASH BALANCE OF $294M AS OF SEPTEMBER 30, 2017 TO SUPPORT ADVANCING RESEARCH AND DEVELOPMENT PROGRAMS Source text for Eikon: Further company coverage:",
    "published": "2018-01-05T14:33:00.000+02:00",
    "crawled": "2018-01-05T14:48:57.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "pharmaceutical",
        "say",
        "phase",
        "clinical",
        "study",
        "respiratory",
        "syncytial",
        "virus",
        "initiated",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "enanta",
        "pharmaceutical",
        "inc",
        "enanta",
        "pharmaceutical",
        "provide",
        "update",
        "research",
        "development",
        "program",
        "business",
        "outlook",
        "36th",
        "annual",
        "morgan",
        "healthcare",
        "conference",
        "enanta",
        "pharmaceutical",
        "inc",
        "phase",
        "clinical",
        "study",
        "respiratory",
        "syncytial",
        "virus",
        "initiated",
        "enanta",
        "pharmaceutical",
        "inc",
        "phase",
        "clinical",
        "study",
        "intrepid",
        "patient",
        "primary",
        "biliary",
        "cholangitis",
        "initiated",
        "enanta",
        "pharmaceutical",
        "inc",
        "strong",
        "cash",
        "balance",
        "294m",
        "september",
        "support",
        "advancing",
        "research",
        "development",
        "program",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}